News and Announcements
OncoPac Global Clinical Study Receives Ethics Approval from Monash Health
- Published February 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is a medical device company that focuses on localised treatments for patients with pancreatic and liver cancer. The Company are pleased to announce that they have been granted the Ethical Approval from the Monash Health for its OncoPac global clinical study program that is specialised for pancreatic cancer.
This study will provide a significant clinical study process to date. The Ethics Approval at Monash Health will also facilitate ethics approval for other participating study centres Australia-wide (excluding Western Australia); this in turn will help accelerate the patient recruitment process.
The success of this grant taking place at Monash Health comes after the Company filed its Ethics Committee (HREC) submission during November last year. Monash Health is the largest public health service in Melbourne, that has agreed to lead this Australian study. Monash provides health care services to over 1.5million people per year. This particular health care facility has also be named one of Victoria’s premier cancer facilities.
To date, OncoSil Medical has confirmed the participation of 12 centres for its global pancreatic clinical study program, along with currently being involved in further discussion with seven centres in the UK, Europe and Australia. The Company, will soon start adding new centres to its trail program in the coming months, along with commencing patient recruitment globally.
OnocSil Medical will update the market on the progress of the OncoPaC clinical study program in due course.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global OncoPaC clinical study program in pancreatic cancer at Monash Health. Monash is a highly regarded cancer centre and is also the lead Australian centre for our clinical study program. With Ethics Approval granted at Monash, it now paves the way for the provision of ethics approvals across other Australian study centres, a pivotal requirement in the study program.”
To view the full announcement, please click here.
Company Updates
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
Backed By Leading Investment Groups and Family Offices
